Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Richard A. Heyman sold 1,270 shares of Enliven Therapeutics stock in a transaction on Monday, April 15th. The shares were sold at an average price of $19.99, for a total value of $25,387.30. Following the completion of the transaction, the director now owns 137,155 shares in the company, valued at $2,741,728.45. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Enliven Therapeutics Price Performance
NASDAQ:ELVN traded down $1.14 during mid-day trading on Monday, hitting $19.94. The company's stock had a trading volume of 745,161 shares, compared to its average volume of 218,023. The business's fifty day moving average is $16.77 and its two-hundred day moving average is $14.21. The stock has a market cap of $821.53 million, a price-to-earnings ratio of -9.03 and a beta of 1.06. Enliven Therapeutics, Inc. has a 1 year low of $9.80 and a 1 year high of $26.00.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its earnings results on Thursday, March 14th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.09. Analysts anticipate that Enliven Therapeutics, Inc. will post -2.16 EPS for the current fiscal year.
Hedge Funds Weigh In On Enliven Therapeutics
A number of hedge funds have recently bought and sold shares of ELVN. Tower Research Capital LLC TRC purchased a new position in Enliven Therapeutics during the first quarter worth approximately $36,000. Ameritas Investment Partners Inc. purchased a new position in shares of Enliven Therapeutics during the 2nd quarter worth $39,000. AJOVista LLC purchased a new stake in shares of Enliven Therapeutics in the 4th quarter valued at approximately $28,000. Royal Bank of Canada boosted its holdings in Enliven Therapeutics by 532.7% in the second quarter. Royal Bank of Canada now owns 3,075 shares of the company's stock valued at $63,000 after purchasing an additional 2,589 shares during the period. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Enliven Therapeutics in the fourth quarter valued at $66,000. Hedge funds and other institutional investors own 95.08% of the company's stock.
Analyst Ratings Changes
Separately, Mizuho started coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They set a "buy" rating and a $34.00 target price for the company.
View Our Latest Stock Analysis on Enliven Therapeutics
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
